Advertisement

Topics

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

2014-07-23 21:13:38 | BioPortfolio

Summary

This study will assess the effectiveness and safety of pasireotide long-acting release in patients who have rare tumors of neuroendocrine origin.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Pancreatic Neoplasm

Intervention

Pasireotide LAR

Location

Novartis Investigative Site
Bron
France

Status

Recruiting

Source

Novartis

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-23T21:13:38-0400

Clinical Trials [1107 Associated Clinical Trials listed on BioPortfolio]

Pasireotide Treatment for Neuroendocrine Tumor

Pasireotide binds to somatostatin receptors sst2 and sst5, which can lead to significant hyperglycemia. The investigators would like to administer pasireotide as a treatment for refractory...

Pasireotide LAR and Pegvisomant Study in Acromegaly

The objective of this study is to assess the efficacy of Pasireotide LAR alone and in combination with weekly Pegvisomant in acromegaIy patients previously controlled with combination trea...

Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease

This is a non-interventional, multinational, multi-center post-marketing study, to further document the safety and efficacy of pasireotide s.c. administered in routine clinical practice in...

Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment

Background: Pasireotide treatment is strictly associated with glucose metabolism impairment. The aim of the study was to evaluate the effect of pasireotide on β -cell and adipose function...

Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)

The goal of this clinical research study is to learn if the study drug, Pasireotide LAR can shrink or slow the growth of Metastatic Neuroendocrine Carcinomas. The safety of this drug will...

PubMed Articles [1523 Associated PubMed Articles listed on BioPortfolio]

Outcomes after Pancreatectomy with Routine Pasireotide Usage.

Morbidity following pancreatectomy is commonly due to leakage of exocrine secretions resulting in abscess or pancreatic fistula (PF). Previously, we authored a double-blind randomized controlled trial...

Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression.

The response to first-generation somatostatin receptor ligands (SRLs) treatment in acromegaly correlates with expression of somatostatin receptor subtype 2 (SSTR2). However, pasireotide shows the high...

Computed tomography and magnetic resonance imaging findings of pancreatic hamartoma: A case report and literature review.

Pancreatic hamartoma is a rare benign malformation that resembles a neoplasm and may be mistaken for a malignancy. The imaging findings of pancreatic hamartoma are not well established, as only one ra...

Rare pancreatic masses: a pictorial review of radiological concepts.

Non-ductal pancreatic neoplasm (NPN) represents a heterogeneous group of pancreatic masses, in which diagnosis and management remain challenging due to their overall rarity. Knowledge of their radiolo...

Trefoil factor 1 inhibits epithelial-mesenchymal transition of pancreatic intraepithelial neoplasm.

The tumor-suppressive role of trefoil factor family (TFF) members has been suggested in gastric carcinogenesis, but their significance and mechanisms in other digestive diseases remain elusive. To cla...

Medical and Biotech [MESH] Definitions

A primary malignant neoplasm of the pancreatic ISLET CELLS. Usually it involves the non-INSULIN-producing cell types, the PANCREATIC ALPHA CELLS and the pancreatic delta cells (SOMATOSTATIN-SECRETING CELLS) in GLUCAGONOMA and SOMATOSTATINOMA, respectively.

Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.

A 36-amino acid pancreatic hormone that is secreted mainly by endocrine cells found at the periphery of the ISLETS OF LANGERHANS and adjacent to cells containing SOMATOSTATIN and GLUCAGON. Pancreatic polypeptide (PP), when administered peripherally, can suppress gastric secretion, gastric emptying, pancreatic enzyme secretion, and appetite. A lack of pancreatic polypeptide (PP) has been associated with OBESITY in rats and mice.

Extracts prepared from pancreatic tissue that may contain the pancreatic enzymes or other specific uncharacterized factors or proteins with specific activities. PANCREATIN is a specific extract containing digestive enzymes and used to treat pancreatic insufficiency.

A pancreatic trypsin inhibitor common to all mammals. It is secreted with the zymogens into the pancreatic juice. It is a protein composed of 56 amino acid residues and is different in amino acid composition and physiological activity from the Kunitz bovine pancreatic trypsin inhibitor (APROTININ).

More From BioPortfolio on "Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pancreatitis
Pancreatitis Acute pancreatitis is inflammation of the pancreas caused by the release of activated pancreatic enzymes. Common triggers are biliary tract disease and chronic heavy alcohol intake.  Diagnosis is based on clinical presentation...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Searches Linking to this Trial